Viral Vector Manufacturing Market Set for Strong Growth to USD 3.8 Billion by 2031, Led by North America's Over 49% Global Market Share | DataM Intelligence

The Global Viral Vector Manufacturing Market reached USD 0.9 billion in 2022 and is projected to reach USD 3.8 billion by 2031, growing at a strong CAGR of 20.3% during 2024-2031.

Market growth is driven by increasing demand for gene therapies and cell-based treatments, rising investments in biopharmaceutical R&D, and expanding applications of viral vectors in vaccine development. Additionally, advancements in vector engineering and the growing number of clinical trials utilizing viral vectors are further accelerating market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/viral-vector-manufacturing-market?ram

United States: Key Industry Developments
✅ November 2025: WuXi Biologics expanded its viral vector production capacity in the US with a new facility in Philadelphia, focusing on AAV and lentiviral vectors to support surging gene therapy demands amid clinical trial accelerations.​

✅ October 2025: Thermo Fisher Scientific launched an upgraded viral vector purification platform in California, incorporating AI-driven analytics for higher yields and purity in AAV manufacturing processes.​

✅ September 2025: Lonza announced a major partnership with a US biotech firm for scalable lentiviral vector production at its Portsmouth site, targeting CAR-T therapies with enhanced biosafety protocols.​

Asia Pacific / Japan: Key Industry Developments
✅ November 2025: China's government allocated USD 4.17 billion for biomanufacturing expansions, including viral vector lines in Shanghai to boost local gene therapy production.​

✅ October 2025: Japan's PMDA issued new guidelines for in-vivo AAV vectors, spurring Takeda Pharmaceutical to upgrade its Kawasaki facility for commercial-scale viral vector manufacturing.​

✅ September 2025: WuXi Biologics opened additional AAV production suites in Suzhou, China, reporting revenue growth funding capacity for Asia-Pacific gene therapy outsourcing.​

Key Merges and Acquisitions(2025):
✅ Thermo Fisher Scientific - partnered with Dr. Park CDMO in September 2025 to equip a new viral vector manufacturing facility, enhancing commercial-scale production for cell and gene therapies.​

✅ Charles River Laboratories - announced a strategic collaboration with Elly's Team in July 2025 to advance gene therapies for rare diseases, leveraging integrated viral vector solutions from preclinical to GMP manufacturing.​

✅ Charles River Laboratories - previously acquired Vigene Biosciences to enter the viral vector manufacturing space, focusing on preclinical and early-phase clinical production with expanded U.S.-based capabilities.​

Market Segmentation Analysis:
-By Type: AAV Vectors Lead with Dominant Share
Adeno-Associated Viral (AAV) Vectors hold the largest market share at 40% in 2025, favored for their low immunogenicity, efficient gene delivery to both dividing and non-dividing cells, and strong safety profile in gene therapies.​
Adenoviral Vectors capture 25%, excelling in high transduction efficiency for vaccines and cancer treatments despite immune response risks.​
Retroviral Vectors account for 20%, primarily used for stable gene integration in dividing cells like hematopoietic therapies, while Other Viral Vectors (e.g., lentiviral) take 15% with rapid growth potential.​
AAV Vectors lead overall by type.​

-By Disease: Cancer Commands Largest Segment
Cancer dominates with 35% market share, driven by oncolytic virotherapies and targeted gene delivery amid rising oncology pipelines.​
Genetic Disorders follow at 30%, boosted by curative outcomes in hemophilia and sickle cell via premium pricing and payer adoption.​
Infectious Diseases hold 25%, fueled by vaccine demands, with Other Diseases at 10% covering niche areas like neurological conditions.​
Cancer leads overall by disease.​

-By Application: Gene Therapy Drives Growth
Gene Therapy leads with 55% share, propelled by in-vivo and ex-vivo therapies like CAR-T for personalized medicine scalability.​
Vaccinology contributes 45%, critical for infectious disease prevention and rapid pandemic responses with established manufacturing.​
Gene Therapy leads overall by application.​

-By End User: Pharma/Biopharma Firms Dominate
Pharmaceutical and Biopharmaceutical Companies command 60% market share, leveraging in-house scale-up and commercialization for blockbuster therapies.​
Research Institutes take 25%, focusing on early R&D pipelines, while CDMOs/CROs hold 15% via outsourced expertise for clinical trials.​
Pharma/Biopharma leads overall by end user.​

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=viral-vector-manufacturing-market?ram (Purchase 2 or more Reports and get 50% Discount)

Growth Drivers:
-Rising prevalence of genetic disorders, cancer, and infectious diseases fuels demand for viral vector-based therapies.​

-Availability of funding and investments for gene therapy research and development accelerates market expansion.​

-Effectiveness of viral vectors in precise gene delivery enhances their adoption in cell and gene therapies.​

-Ongoing advancements in bioprocessing, such as improved cell lines and scalable production technologies, boost manufacturing efficiency.​

-Increasing clinical trials and regulatory approvals for gene therapies drive higher production needs.​

Regional Insights:
-North America leads the viral vector manufacturing market with over 49% share in 2024, driven by advanced biotechnology infrastructure, high clinical trial activity, and substantial R&D investments from leading pharmaceutical companies in the US and Canada. The region valued at USD 4.20 billion in 2024 is projected to grow to USD 4.5 billion in 2025 at a CAGR of 7.16% through 2034, fueled by rising gene therapy demand and innovations in scalable production.​

-Europe follows as the second-largest region, benefiting from strong regulatory frameworks, expanding biotech hubs, and increasing gene therapy approvals, though exact share figures lag behind North America amid fragmented manufacturing capacities.​

-Asia Pacific ranks third, showing rapid growth potential due to emerging contract manufacturing organizations, government investments in biopharma, and clinical trial expansions in countries like China and India, yet it holds a smaller overall market share compared to North America and Europe.​

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/viral-vector-manufacturing-market?ram

Key Players:
Sanofi SA | Thermo Fisher Scientific Inc. | Cobra Biologics Ltd | Lonza Group Ltd | Merck & Co. | Oxford BioMedica | CGT Catapult | UniQure NV | FUJIFILM Diosynth Biotechnologies | Spark Therapeutics Inc.

Key Highlights (Top 5 Key Players) for Viral Vector Manufacturing Market:
-Thermo Fisher Scientific Inc. leads with estimated annual revenues exceeding USD 1.5 billion in biopharma services, including viral vector production capacity expansions for AAV and lentiviral therapies growing 25% YoY.

-Lonza Group Ltd reported USD 1.2 billion from cell and gene therapy manufacturing in 2024, driven by new viral vector facilities supporting over 50 gene therapy programs.

-FUJIFILM Diosynth Biotechnologies generated USD 900 million in advanced therapies revenue, with viral vector yields improved 40% through proprietary HEK293 platforms for commercial-scale AAV production.

-Merck & Co. achieved USD 750 million in bioprocessing revenues tied to viral vector plasmids and downstream purification, bolstered by Merck KGaA partnerships for global supply.

-Oxford BioMedica recorded USD 450 million from lentiviral vector manufacturing services, capturing 15% market share in clinical-stage gene therapies with LentiVector platform scalability.

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.